Role of hyperinsulinemia in increased risk of prostate cancer: A case control study from Kathmandu valley

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 1031-1033

  Pandeya, Dipendra Raj ^a   Mittal, Ankush ^a   Sathian, Brijesh ^a   Bhatta, Bibek ^a  

^a Nepalese Army Institute of Health Sciences   (Nepal)

Author keywords

Hyperinsulinemia; Kathmandu; Prostate cancer; Risk

Indexed keywords

INSULIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN RESISTANCE; MALE; METABOLISM; NEPAL; PROGNOSIS; PROSTATE TUMOR; RISK FACTOR;

ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE; NEPAL; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894660724     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.1031     Document Type: Article

References (17)

1. Albanes D, Weinstein SJ, Wright ME, et al (2009). Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst, 101, 1272-9.
2. Asafudullah SM, Salam MA, Badruddoza SM (2011). Evaluation of diagnostic accuracy of different biomarkers for prostate cancer. Pak J Med Sci, 27, 48-51.
3. Belbase NP, Agrawal CS, Pokharel PK, et al (2013). Prostate cancer screening in a healthy population cohort in eastern Nepal: an explanatory trial study. Asian Pac J Cancer Prev, 14, 2835-8.
4. Cox ME, Gleave ME, Zakikhani M, et al (2009). Insulin receptor expression by human prostate cancers. Prostate, 69, 33-40.
5. De Loureiro JA, Janz GJ (1944). Iodometric and colorimetric methods for the estimation of calcium in serum based on the use of an improved permanganate solution. Biochem J, 38, 16-9.
6. Ding J, Tang J, Chen X, et al (2013). Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus. Asian Pac J Cancer Prev, 14, 5675-80.
7. Esposito K, Chiodini P, Capuano A, et al (2013). Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest, 36, 132-9.
8. Haas GP, Sakr WA (1997). Epidemiology of prostate cancer. CA Cancer J Clin, 47, 273-87.
9. Kahn CR, Rosenthal AS (1979). Immunologic reactions to insulin, insulin allergy, insulin resistance and autoimmune insulin syndrome. Diabetes Care, 2, 283-95.
10. Morss AS, Edelman ER (2007). Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem, 282, 14635-44.
11. Pollak M (2012). The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer, 12, 159-69.
12. Richardson LC, Pollack LA (2005). Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol, 2, 48-53.
13. Trinder P (1969). Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem, 6, 24-7.
14. Trinder P (1969). Determination of serum cholesterol by enzymatic colorimetric method. Ann Clin Biochem, 6, 24-7.
15. Xiang YZ, Xiong H, Cui ZL, et al (2013). The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res, 32, 9.
16. Xiong ZP, Huang F, Lu MH, et al (2012). Association between insulin-like growth factor-2 expression and prognosis after transcatheterarterial chemoembolization and octreotide in patients with hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 3191-4.
17. Zhang YR, Xu Y, Yang K, et al (2012). Association of six susceptibility loci with prostate cancer in northern Chinese men. Asian Pac J Cancer Prev, 13, 6273-6.